| Arthur C Martin, MD | |
|
415 S 28th Ave, Hattiesburg, MS 39401-7246 | |
| (601) 268-5800 | |
| (601) 261-3530 |
| Full Name | Arthur C Martin |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 44 Years |
| Location | 415 S 28th Ave, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821103185 | NPI | - | NPPES |
| 1559344 | Other | MS | AMERICAN ADMIN GROUP |
| 00124264 | Medicaid | MS | |
| 1419605 | Medicaid | LA | |
| 009925685 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 17330 (Mississippi) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 17330 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Forrest General Hospital | Hattiesburg, MS | Hospital |
| Walthall County General Hospital Cah | Tylertown, MS | Hospital |
| South Central Reg Med Ctr | Laurel, MS | Hospital |
| Covington County Hospital Cah | Collins, MS | Hospital |
| Pearl River County Hospital | Poplarville, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forrest County General Hospital | 1052397767 | 85 |
| Fgh Physician Billing | 1850344946 | 23 |
| Walthall General Hospital | 3678766094 | 6 |
| Hattiesburg Clinic, Pa | 5193706794 | 489 |
News Archive
Better educational opportunities and higher incomes may be key to closing the gap of cardiovascular health behaviors-including smoking, physical activity, and diet quality-between black and white Americans, according to a new study led by a University of Iowa researcher.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Ellipse Technologies announced today that preliminary clinical data suggests children with Early Onset Scoliosis (EOS) can be treated safely and effectively without the conventional protocol of repeated surgeries to straighten their growing spine.
Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 1 days ago
| Entity Name | Hattiesburg Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740213446 PECOS PAC ID: 5193706794 Enrollment ID: O20040528000685 |
News Archive
Better educational opportunities and higher incomes may be key to closing the gap of cardiovascular health behaviors-including smoking, physical activity, and diet quality-between black and white Americans, according to a new study led by a University of Iowa researcher.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Ellipse Technologies announced today that preliminary clinical data suggests children with Early Onset Scoliosis (EOS) can be treated safely and effectively without the conventional protocol of repeated surgeries to straighten their growing spine.
Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 1 days ago
| Entity Name | Forrest County General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295837631 PECOS PAC ID: 1052397767 Enrollment ID: O20040624001351 |
News Archive
Better educational opportunities and higher incomes may be key to closing the gap of cardiovascular health behaviors-including smoking, physical activity, and diet quality-between black and white Americans, according to a new study led by a University of Iowa researcher.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Ellipse Technologies announced today that preliminary clinical data suggests children with Early Onset Scoliosis (EOS) can be treated safely and effectively without the conventional protocol of repeated surgeries to straighten their growing spine.
Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 1 days ago
| Entity Name | Fgh Physician Billing |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053469700 PECOS PAC ID: 1850344946 Enrollment ID: O20050301000617 |
News Archive
Better educational opportunities and higher incomes may be key to closing the gap of cardiovascular health behaviors-including smoking, physical activity, and diet quality-between black and white Americans, according to a new study led by a University of Iowa researcher.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Ellipse Technologies announced today that preliminary clinical data suggests children with Early Onset Scoliosis (EOS) can be treated safely and effectively without the conventional protocol of repeated surgeries to straighten their growing spine.
Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 1 days ago
| Entity Name | Walthall General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245512417 PECOS PAC ID: 3678766094 Enrollment ID: O20111103000238 |
News Archive
Better educational opportunities and higher incomes may be key to closing the gap of cardiovascular health behaviors-including smoking, physical activity, and diet quality-between black and white Americans, according to a new study led by a University of Iowa researcher.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Ellipse Technologies announced today that preliminary clinical data suggests children with Early Onset Scoliosis (EOS) can be treated safely and effectively without the conventional protocol of repeated surgeries to straighten their growing spine.
Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arthur C Martin, MD 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 268-5800 | Arthur C Martin, MD 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 268-5800 |
News Archive
Better educational opportunities and higher incomes may be key to closing the gap of cardiovascular health behaviors-including smoking, physical activity, and diet quality-between black and white Americans, according to a new study led by a University of Iowa researcher.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Ellipse Technologies announced today that preliminary clinical data suggests children with Early Onset Scoliosis (EOS) can be treated safely and effectively without the conventional protocol of repeated surgeries to straighten their growing spine.
Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 1 days ago
Laurie Evans Douglas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-261-1700 Fax: 601-288-8290 | |
Dr. Charles Ramsey Mccollum Iii, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5650 Fax: 601-579-5212 | |
Porter Hudson Glover, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5680 Fax: 601-268-5778 | |
Alex Gauthier, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-268-8000 | |
Grettel Rodriguez Garcia, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 31 Woodstone Dr, Hattiesburg, MS 39402 Phone: 347-342-2441 | |
Ms. Manal Mohammad Abdur Rahman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7 Medical Blvd, Hattiesburg, MS 39401 Phone: 601-296-2990 Fax: 601-296-2860 | |
Dr. Vashishtha Patel, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 704-733-7499 |